C4 Therapeutics (CCCC) Liabilities and Shareholders Equity (2019 - 2026)

C4 Therapeutics has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $328.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 2.92% year-over-year to $328.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (down 12.36% YoY), and the FY2025 full-year result was $359.1 million, up 2.71% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $328.9 million, down from $359.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $515.5 million in Q1 2022, with the low at $265.5 million in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $379.7 million, with a median of $376.1 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity surged 37.83% in 2022 and fell 29.4% in 2025.
• Tracing CCCC's Liabilities and Shareholders Equity over 5 years: stood at $430.8 million in 2022, then decreased by 12.62% to $376.5 million in 2023, then declined by 7.13% to $349.6 million in 2024, then rose by 2.71% to $359.1 million in 2025, then dropped by 8.41% to $328.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $328.9 million (Q1 2026), $359.1 million (Q4 2025), and $265.5 million (Q3 2025), per Business Quant data.

Peer Comparison